William Blair Lifts Earnings Estimates for Twist Bioscience

Twist Bioscience Co. (NASDAQ:TWST - Free Report) - Investment analysts at William Blair lifted their Q2 2025 EPS estimates for Twist Bioscience in a research report issued to clients and investors on Tuesday, February 4th. William Blair analyst M. Larew now anticipates that the company will post earnings per share of ($0.55) for the quarter, up from their prior forecast of ($0.57). The consensus estimate for Twist Bioscience's current full-year earnings is ($2.12) per share. William Blair also issued estimates for Twist Bioscience's Q3 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.07) EPS, Q1 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.28) EPS and FY2026 earnings at ($1.49) EPS.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company's quarterly revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.75) earnings per share.

Several other equities research analysts also recently weighed in on TWST. Wolfe Research assumed coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 price target for the company. Robert W. Baird upped their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a report on Tuesday, February 4th. Scotiabank lifted their price target on shares of Twist Bioscience from $54.00 to $62.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, February 4th. JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 4th. Finally, Leerink Partners lifted their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $53.80.

Twist Bioscience Stock Down 7.0 %

NASDAQ:TWST traded down $3.69 during trading hours on Thursday, reaching $48.62. 1,218,243 shares of the company traded hands, compared to its average volume of 808,532. The company has a current ratio of 4.96, a quick ratio of 4.54 and a debt-to-equity ratio of 0.03. The business's 50-day moving average price is $48.91 and its two-hundred day moving average price is $46.13. Twist Bioscience has a 1 year low of $27.41 and a 1 year high of $60.90. The stock has a market capitalization of $2.90 billion, a P/E ratio of -14.38 and a beta of 1.87.

Insider Activity

In related news, Director Robert Chess sold 3,504 shares of the business's stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $51.85, for a total value of $181,682.40. Following the completion of the transaction, the director now owns 21,641 shares of the company's stock, valued at $1,122,085.85. The trade was a 13.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Paula Green sold 860 shares of the stock in a transaction on Friday, December 6th. The shares were sold at an average price of $52.70, for a total value of $45,322.00. Following the sale, the senior vice president now directly owns 133,715 shares in the company, valued at $7,046,780.50. This trade represents a 0.64 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,240 shares of company stock worth $1,665,769. Company insiders own 3.01% of the company's stock.

Institutional Trading of Twist Bioscience

Several hedge funds have recently modified their holdings of TWST. Swiss National Bank raised its position in shares of Twist Bioscience by 1.1% in the 4th quarter. Swiss National Bank now owns 115,200 shares of the company's stock valued at $5,353,000 after purchasing an additional 1,200 shares during the last quarter. Farther Finance Advisors LLC lifted its position in Twist Bioscience by 59.6% during the 4th quarter. Farther Finance Advisors LLC now owns 5,429 shares of the company's stock worth $252,000 after acquiring an additional 2,028 shares during the period. Wealthfront Advisers LLC purchased a new stake in Twist Bioscience during the 4th quarter valued at about $209,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Twist Bioscience by 5.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,064 shares of the company's stock valued at $793,000 after purchasing an additional 821 shares during the period. Finally, AlphaQuest LLC raised its stake in shares of Twist Bioscience by 216.9% in the fourth quarter. AlphaQuest LLC now owns 11,422 shares of the company's stock worth $531,000 after purchasing an additional 7,818 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.